Company intelligence / Profile preview
Abrexa Pharmaceuticals
San Diego, California, United Stateskando.tech ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Abrexa Pharmaceuticals is developing J147, an oral small molecule derived from curcumin, targeting neurodegenerative diseases. A completed Phase I trial demonstrated safety and tolerability in healthy volunteers. Preclinical data suggest efficacy against acute ischemic stroke and potential benefits in aging models. The approach differs from traditional amyloid-targeting Alzheimer’s drugs by focusing on anti-aging mechanisms.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Cedars-Sinai Medical Center
Beyond the preview
Go deeper on Abrexa Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abrexa Pharmaceuticals.